Señales en vivo de 1349.HK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 02:12):

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products...

Stats
Volumen de hoy	14 000.00
Volumen promedio	665 603
Capitalización de mercado	704.16M
EPS	HKD0.0500 ( 2020-09-30 )
Last Dividend	HKD0.0798 ( 2023-06-05 )
Next Dividend	HKD0 ( N/A )
P/E	19.64
ATR14	HKD0.00800 (0.37%)

FUDANZHANGJIANG Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

FUDANZHANGJIANG Finanzas

Annual	2023
Ingresos:	HKD850.73M
Beneficio Bruto:	HKD776.66M (91.29 %)
EPS:	HKD0.110

FY	2023
Ingresos:	HKD850.73M
Beneficio Bruto:	HKD776.66M (91.29 %)
EPS:	HKD0.110

FY	2022
Ingresos:	HKD1.03B
Beneficio Bruto:	HKD947.10M (91.85 %)
EPS:	HKD0.130

FY	2021
Ingresos:	HKD1.14B
Beneficio Bruto:	HKD1.06B (92.90 %)
EPS:	HKD0.210

Financial Reports:

No articles found.

FUDANZHANGJIANG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0859 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0798 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

FUDANZHANGJIANG Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.51 - Decrease likely (29.87%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0623	2015-06-04
Last Dividend	HKD0.0798	2023-06-05
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	9	--
Total Paid Out	HKD0.566	--
Avg. Dividend % Per Year	0.00%	--
Score	3	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.51
Div. Directional Score	8.04	--

Next Divdend (Est)
(2025-04-07)

HKD0.0845 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.00

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3888.HK	Ex Dividend Junior	2023-06-02	Annually	0.00%
1739.HK	No Dividend Player	2023-09-05	Sporadic	0.00%
0777.HK	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%
2333.HK	Ex Dividend Knight	2023-06-29	Annually	0.00%
1308.HK	Ex Dividend Knight	2023-08-28	Semi-Annually	0.00%
0366.HK	Ex Dividend Knight	2023-09-25	Semi-Annually	0.00%
6178.HK	Ex Dividend Junior	2023-07-12	Annually	0.00%
1861.HK	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%
0883.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%
0026.HK	Ex Dividend Junior	2023-10-03	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.126	1.500	7.47	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0362	1.200	8.79	10.00	[0 - 0.3]
returnOnEquityTTM	0.0436	1.500	-0.627	-0.940	[0.1 - 1]
payoutRatioTTM	0.725	-1.000	2.75	-2.75	[0 - 1]
currentRatioTTM	4.05	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.90	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.72	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00523	-1.500	9.91	-10.00	[0 - 0.6]
interestCoverageTTM	94.34	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	0.254	2.00	9.92	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.200	2.00	9.90	10.00	[0 - 20]
debtEquityRatioTTM	0.00626	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.915	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.101	1.000	9.99	9.99	[0.1 - 0.6]
cashFlowToDebtRatioTTM	18.63	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.286	0.800	-1.424	-1.139	[0.5 - 2]
Total Score				12.57

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	21.23	1.000	7.96	0	[1 - 100]
returnOnEquityTTM	0.0436	2.50	-0.403	-0.940	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.200	2.00	9.93	10.00	[0 - 30]
dividendYielPercentageTTM	3.99	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.254	2.00	9.92	10.00	[0 - 30]
payoutRatioTTM	0.725	1.500	2.75	-2.75	[0 - 1]
pegRatioTTM	-0.716	1.500	-8.11	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.340	1.000	4.00	0	[0.1 - 0.5]
Total Score				3.51

FUDANZHANGJIANG

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.